Evidence map›Paper›PMID 38074504›Full record

ArticleJHEP reports : innovation in hepatology2024

Cholangiocarcinoma-on-a-chip: A human 3D platform for personalised medicine.

Michela Anna Polidoro, Erika Ferrari, Cristiana Soldani, Barbara Franceschini, Giuseppe Saladino, Arianna Rosina, Andrea Mainardi, Francesca D'Autilia, Nicola Pugliese, Guido Costa and 5 more

Open access · goldAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Michela Anna PolidoroHepatobiliary Immunopathology Laboratory, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Erika FerrariDepartment of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
Cristiana SoldaniHepatobiliary Immunopathology Laboratory, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Barbara FranceschiniHepatobiliary Immunopathology Laboratory, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Giuseppe SaladinoDepartment of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
Arianna RosinaDepartment of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
Andrea MainardiDepartment of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
Francesca D'AutiliaUnit of Advanced Optical Microscopy, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Nicola PuglieseDepartment of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, Italy.
Guido CostaDivision of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Matteo DonadonDepartment of Health Sciences, Università del Piemonte Orientale, Novara, Italy.
Guido TorzilliDepartment of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, Italy.
Simona MarzoratiHepatobiliary Immunopathology Laboratory, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Marco RasponiDepartment of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
Ana LleoDepartment of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, Italy.
IRCCS Humanitas Research Hospital · ITPolitecnico di Milano · ITHumanitas University · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Cholangiocarcinoma (CCA) is a primary liver tumour characterised by a poor prognosis and limited therapeutic options. Available 3D human CCA models fail to faithfully recapitulate the tumour niche. We aimed to develop an innovative patient-specific CCA-on-chip platform. Methods: A CCA tumour microenvironment was recapitulated on a microfluidic three-channel chip using primary CCA cells, cancer-associated fibroblasts (CAFs), endothelial cells, and T cells isolated from CCA specimens (n = 6). CAF and CCA cells were co-cultured in the central channel, flanked by endothelial cells in one lateral channel, recreating a tubular structure. An extensive characterisation of this platform was carried out to investigate its diffusion ability, hydrogel properties, and changes in matrix composition. Cell phenotype and functional properties were assessed. Results: Primary cells seeded on the microfluidic device were shown to reproduce the architectural structure and maintain the original phenotype and functional properties. The tumour niche underwent a deep remodelling in the 3D device, with an increase in hydrogel stiffness and extracellular matrix deposition, mimicking Conclusions: We presented a 3D CCA platform that integrates the major non-immune components of the tumour microenvironment and the T cell infiltrate, reflecting the CCA niche. This CCA-on-chip represents a reliable patient-specific 3D platform that will be of help to further elucidate the biological mechanisms involved in CCA and provide an efficient tool for personalised drug testing. Impact and implications: An innovative patient-specific cholangiocarcinoma (CCA)-on-chip platform was successfully developed, integrating the major components of the tumour microenvironment (tumour cells, cancer-associated fibroblasts, endothelial cells, and immune infiltrate) and faithfully mimicking the CCA niche. This CCA-on-chip represents a powerful tool for unravelling disease-associated cellular mechanisms in CCA and provides an efficient tool for personalised drug testing.

Indexed as

Cell–cell crosstalkCholangiocarcinomaDrug testingLiver-on-chipMicrofluidicsTumour microenvironment

Identifiers

PMID38074504
PMCPMC10698278
OpenAlexW4386776203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.